Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

University of Westminster

- PMLiVE

NHS bowel cancer checks reach record-high following death of Dame Deborah James

Between May and July 2022, over 170,500 people were referred for suspected lower gastro-intestinal cancers – up over 30,000 compared to the same period last year

- PMLiVE

NHS England outlines measures to boost capacity ahead of substantial winter pressures

The package of measures includes creating the equivalent of 7,000 additional hospital beds

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

- PMLiVE

Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection

Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion

- PMLiVE

Over 47,000 stroke patients to miss out on ‘game-changing’ treatment, the Stroke Association warns

This year, NHS England failed to reach its original target to make mechanical thrombectomy available to all suitable patients

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on CLL

Spotlight on CLLAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Prof John Gribben, UK, on the most important abstracts to look out for in...

Medscape Education Global

- PMLiVE

The White House reveals its ‘Cancer Cabinet’ line-up as its Moonshot initiative progresses

The panel includes its new chairperson, Elizabeth Jaffee, Mitchel Berger and Carol Brown

- PMLiVE

Researchers create ‘world’s largest’ database for predicting cancer treatment response

The database will be available to cancer researchers and clinicians around the world

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

Novartis announces positive phase 3 trial results for advanced oesophageal cancer

Results from the study showed tislelizumab plus chemotherapy significantly improved overall survival for patients, regardless of PD-L1 status

- PMLiVE

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

The recommendation makes Scemblix the first treatment in its class to be authorised in Britain

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links